Zusammenfassung
Die Behandlung kardiovaskulärer, metabolischer und maligner
Erkrankungen HIV-Infizierter gewinnt zunehmend an Bedeutung. Eine
Intensivierung der Krebsvorsorgeuntersuchungen wird empfohlen; Daten,
die eine Reduktion der Tumorinzidenz oder tumorassoziierten Mortalität
belegen, sind jedoch rar. Der optimale Zeitpunkt des Starts der
antiretroviralen Therapie ist umstritten. Unter früherem
Therapiebeginn konnte erstmals gezeigt werden, dass die HIV-Ansteckungsrate
signifikant sinkt.
Abstract
The treatment of cardiovascular, metabolic and malignant diseases
is playing an increasing role in HIV-infected patients. Intensified
cancer screening is recommended, but data demonstrating a reduction
of tumour incidence or tumour-associated mortality are rare. Controversy
exists about the best time point of initiation of antiretroviral
therapy. Recently, data indicate that an earlier start could reduce
HIV transmission.
Schlüsselwörter
HIV - chronische Erkrankung - maligne Erkrankungen - Therapiestart - Prävention -
Infektiösität
Keywords
HIV - chronic disease - malignancies - initiation of ART - prevention - infecitivity
Literatur
- 1
Causes of death in HIV-1-infected
patients treated with antiretroviral therapy, 1996 – 2006:
collaborative analysis of 13 HIV cohort studies.
Clin
Infect Dis.
2010;
50
1387-1396
- 2
Abdool Karim Q. et al .
Effectiveness and safety of tenofovir gel,
an antiretroviral microbicide, for the prevention of HIV infection
in women.
Science.
2010;
329
1168-1174
- 3
Bhaskaran K, Hamouda O, Sannes M. et al .
Changes in the risk of death after HIV
seroconversion compared with mortality in the general population.
JAMA.
2008;
300
51-59
- 4
Grant R M, Lama J R, Anderson P L. et al .
Preexposure chemoprophylaxis
for HIV prevention in men who have sex with men.
New Engl J
Med.
2010;
363
2587-2599
- 5
Kitahata M M, Gange S J, Abraham A G. et al .
Effect of early versus deferred
antiretroviral therapy for HIV on survival.
New Engl J
Med.
2009;
360
1815-1826
- 6 Lalezari J. et al .Successful and persistent engraftment of
ZFN-M-R5-D autologous CD4 T Cells (SB-728-T) in aviremic HIV-infected subjects
on HAART. 18th Conference on Retroviruses and Opportunistic Infections (CROI),. Boston;
2011; Abstract # 46
- 7
Shenfield F, Pennings G, Cohen J. et al .
Taskforce 8: ethics of medically assisted
fertility treatment for HIV positive men and women.
Hum Reprod.
2004;
19
2454-2456
- 8
Shiels M S, Pfeiffer R M, Hall H I. et al .
Proportions of Kaposi sarcoma,
selected non-Hodgkin lymphomas, and cervical cancer in the United States
occurring in persons with AIDS, 1980 – 2007.
JAMA.
2011;
305
1450-1459
- 9
Simard E P, Engels E A.
Cancer as a
cause of death among people with AIDS in the United States.
Clin
Infect Dis.
2010;
51
957-962
- 10
Sterne J A, May M, Costagliola D. et al .
Timing of initiation of antiretroviral
therapy in AIDS-free HIV-1-infected patients: a collaborative analysis
of 18 HIV cohort studies.
Lancet.
2009;
373
1352-1363
- 11
Tandler-Schneider A, Sonnenberg-Schwan U, Gingelmaier A. et al .
Diagnostik und Behandlung
HIV-betroffener Paare mit Kinderwunsch.
Dtsch Med Wochenschr.
2009;
134 Suppl 1
S34-39
- 12
Vernazza P, Hirschel B, Bernasconi E, Flepp M.
HIV transmission under
highly active antiretroviral therapy.
Lancet.
2008;
372
1806-1807; author reply 1807
- 13
Worm S W, Sabin C.
Risk of myocardial infarction
in patients with HIV infection exposed to specific individual antiretroviral
drugs from the 3 major drug classes: the data collection on adverse
events of anti-HIV drugs (D:A:D) study.
J Infect Dis.
2010;
201
318-330
- 14 Deutsch-Österreichische
Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/leitlinien_28 – 05 – 2010_V_late.pdf Letzter Zugriff am 22.5.2011
- 15 National Institutes of
Health .Treating HIV-infected people with antiretrovirals
protects partners from infection. Findings result from NIH-funded
international study. http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx Letzter Zugriff am 22.5.2011
Dr. Norma Jung
Klinik I für Innere Medizin
Uniklinik Köln
Kerpener Str. 62
50937 Köln
Email: norma.jung@uni-koeln.de
